American Association for Cancer Research--99th Annual Meeting. Coverage of AKT and MET pathways and antibody-based therapeutics.
Filson
Sarah
S
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. sarah.filson@thomsonreuters.com
Tidwell
Kerrie
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008545:Melanoma / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy*; D051058:Oncogene Protein v-akt / Q000235:genetics / Q000502:physiology; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D019859:Proto-Oncogene Proteins c-met; D051058:Oncogene Protein v-akt